Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 73
- Registration Number
- NCT00056030
- Locations
- 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸CCOP - Upstate Carolina, Spartanburg, South Carolina, United States
🇺🇸Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States
Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
- Conditions
- First Posted Date
- 2003-02-17
- Last Posted Date
- 2012-03-12
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00054977
- Locations
- 🇺🇸
Florida Oncology Associates, Jacksonville, Florida, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Ochsner Cancer Institute, New Orleans, Louisiana, United States
Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer
- Conditions
- First Posted Date
- 2003-02-13
- Last Posted Date
- 2006-07-11
- Lead Sponsor
- Chiron Corporation
- Registration Number
- NCT00054873
- Locations
- 🇺🇸
Tower Hematology Oncology Medical Group, Los Angeles, California, United States
🇺🇸Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 3010
- Registration Number
- NCT00054587
- Locations
- 🇫🇷
Centre Hospitalier de Mulhouse, Mulhouse, France
🇫🇷Institut Prive de Cancerologie, Grenoble, France
🇫🇷Centre Paul Papin, Angers, France
Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 96
- Registration Number
- NCT00053807
- Locations
- 🇳🇱
Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
🇹🇷Dokuz Eylul University School of Medicine, Izmir, Turkey
🇳🇱Daniel Den Hoed Cancer Center at Erasmus University Medical Center, Rotterdam, Netherlands
S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2011-07-25
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00054054
- Locations
- 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2014-12-16
- Lead Sponsor
- UNICANCER
- Registration Number
- NCT00053911
- Locations
- 🇫🇷
Clinique Claude Bernard, Albi, France
🇫🇷Institut Bergonie, Bordeaux, France
🇫🇷Centre Paul Papin, Angers, France
Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 670
- Registration Number
- NCT00053820
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
🇳🇱Academisch Ziekenhuis Maastricht, Maastricht, Netherlands
🇧🇪Onze Lieve Vrouw Ziekenhuis Aalst, Aalst, Belgium
Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 518
- Registration Number
- NCT00003216
- Locations
- 🇺🇸
CCOP - Duluth, Duluth, Minnesota, United States
🇺🇸Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 200
- Registration Number
- NCT00003637
- Locations
- 🇸🇬
National Cancer Centre - Singapore, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.